Fate Therapeutics, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 33 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $1M | ↓-26.4% | — | — | — |
| 2025-09-30 | $2M | ↓-43.4% | $-32M | ↑+32.4% | -1995.1% |
| 2025-06-30 | $2M | ↓-71.8% | $-34M | ↑+11.3% | -1938.5% |
| 2025-03-31 | $2M | ↓-15.4% | $-38M | ↑+21.6% | -2534.1% |
| 2024-12-31 | $2M | ↑+11.0% | — | — | — |
| 2024-09-30 | $3M | ↑+58.1% | $-48M | ↓-5.6% | -1703.9% |
| 2024-06-30 | $7M | ↑+625.8% | $-38M | ↑+27.2% | -665.7% |
| 2024-03-31 | $2M | ↓-96.7% | $-48M | ↓-154.2% | -2652.9% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$1M
↓-26.4% -$491K YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
FATE Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyFATE Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics